---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-25-000128"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:47:35.145745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M

## Summary
- Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
- Gross margin improved to 76.6% from 74.9% YoY; adjusted EBITDA $9.2M vs $6.5M.
- Raised full-year revenue guidance to at least $222.8M (≥19% growth); gross margin reaffirmed 73-75%.
- FDA PDUFA for Avance Nerve Graft BLA extended to Dec 5, 2025; AAHS and ASRM issued position statements recognizing nerve allografts.
- Added 18.1M covered lives in 2025; commercial payer coverage now over 64%.

## SEC filing metadata
- accession: 0000805928-25-000128
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/0000805928-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592825000128/axgn-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-25-000128
- JSON: https://secwatch.observer/filing/0000805928-25-000128.json
- Plain text: https://secwatch.observer/filing/0000805928-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.